Table 4.

IHC expression for HER family and clinicopathological characters in high-risk GISTs with imatinib adjuvant therapy

	Total	%	EGFR				HER2				HER4
			—	%	+	%	—	%	+	%	—	%	+	%
Age (years)
≤ 50	7	14.6	2	4.2	5	10.4	3	6.3	4	8.3	2	4.2	5	10.4
> 50	41	85.4	21	43.8	20	41.7	18	37.5	23	47.9	20	41.7	21	43.8
Gender
Male	28	58.3	13	27.1	15	31.3	14	29.2	14	29.2	13	27.1	15	31.3
Female	20	41.7	10	20.8	10	20.8	7	14.6	13	27.1	9	18.8	11	22.9
Tumor site
Stomach	18	37.5	11	22.9	7	14.6	9	18.8	9	18.8	9	18.8	9	18.8
Small bowel	23	47.9	9	18.8	14	29.2	9	18.8	14	29.2	10	20.8	13	27.1
Colorectum	3	6.3	2	4.2	1	2.1	1	2.1	2	4.2	2	4.2	1	2.1
Others	4	8.3	1	2.1	3	6.3	2	4.2	2	4.2	1	2.1	3	6.3
Tumor size (cm)
≤ 2.0	1	2.1	0	0.0	1	2.1	0	0.0	1	2.1	1	2.1	0	0.0
2.1-5.0	3	6.3	0	0.0	3	6.3	0	0.0	3	6.3	1	2.1	2	4.2
5.1-10.0	24	50.0	15	31.3	9	18.8	12	25.0	12	25.0	10	20.8	14	29.2
> 10.0	20	41.7	8	16.7	12	25.0	9	18.8	11	22.9	10	20.8	10	20.8
Mitoses per 50 HPFs
≤ 5	17	35.4	7	14.6	10	20.8	7	14.6	10	20.8	6	12.5	11	22.9
6-10	16	33.3	8	16.7	8	16.7	8	16.7	8	16.7	10	20.8	6	12.5
> 10	15	31.3	8	16.7	7	14.6	6	12.5	9	18.8	6	12.5	9	18.8
Total	48	100.0	23	47.9	25	52.1	21	43.8	27	56.3	22	45.8	26	54.2